301201.SHE ChengDa Pharmaceuticals Co. Ltd.
- Market cap
- CNY 3.54B
- P/E
- -
- P/B
- 1.73x
- ROE
- -0.8%
- Dividend yield
- 0.93%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301201.SHE undervalued?
Graham numberThe Graham number of ChengDa Pharmaceuticals Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ChengDa Pharmaceuticals Co. Ltd. fundamental analysis
No fundamental analysis for ChengDa Pharmaceuticals Co. Ltd. yet.
ChengDa Pharmaceuticals Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. …
Full company profileChengDa Pharmaceuticals Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ChengDa Pharmaceuticals Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 294M | 373M | 416M | 411M | 414M | 333M | 406M | 474M |
| Gross Profit | 132M | 187M | 208M | 198M | 178M | 143M | 179M | 143M |
| Operating Income | 71.7M | 104M | 123M | 89.7M | 60.6M | -58.1M | 13.5M | -8.47M |
| EBITDA | 131M | 177M | 147M | 156M | 145M | 20.3M | 62.0M | -15.4M |
| Net Income | 54.2M | 121M | 100M | 106M | 91.0M | -28.1M | -11.9M | -16.6M |
| EPS | 0.75 | 1.04 | 0.87 | 0.69 | 0.59 | -0.18 | -0.08 | -0.11 |
| Balance Sheet | ||||||||
| Total Assets | 547M | 534M | 683M | 2.32B | 2.46B | 2.44B | 2.35B | 2.33B |
| Total Liabilities | 189M | 75.3M | 153M | 106M | 176M | 291M | 253M | 276M |
| Shareholders' Equity | 356M | 458M | 529M | 2.21B | 2.28B | 2.14B | 2.09B | 2.05B |
| Cash & Short-term Investments | 65.6M | 47.0M | 18.5M | 604M | 1.36B | 178M | 726M | 93.2M |
| Cash Flow | ||||||||
| Operating Cash Flow | 67.5M | 129M | 83.1M | 47.7M | 192M | 28.6M | 34.0M | - |
| Capital Expenditure | 51.1M | 63.8M | 139M | 206M | 225M | 286M | 69.0M | 137M |
| Free Cash Flow | 16.5M | 65.2M | -55.6M | -158M | -32.6M | -258M | -35.0M | -52.0M |
| Ratios | ||||||||
| ROE | 15.2% | 26.5% | 19.0% | 4.8% | 4.0% | -1.3% | -0.6% | -0.8% |
| ROA | 9.9% | 22.7% | 14.7% | 4.6% | 3.7% | -1.2% | -0.5% | -0.7% |
| Net Profit Margin | 18.4% | 32.5% | 24.2% | 25.9% | 22.0% | -8.4% | -2.9% | -3.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ChengDa Pharmaceuticals Co. Ltd. dividends
- Dividend yield
- 0.93%
- Forward dividend
- 0.20 CNY
- Payout ratio
- -
- Ex-dividend date
- Jul 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 32.8M | 0.21 | - |
| 2024 | CNY 30.5M | 0.20 | - |
| 2023 | CNY 29.0M | 0.19 | 31.9% |
| 2022 | CNY 43.8M | 0.28 | 41.1% |
| 2021 | CNY 31.3M | 0.27 | 31.2% |
| 2020 | CNY 22.8M | 0.20 | 18.9% |
| 2019 | CNY 28.5M | 0.39 | 52.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.6:1 on Jul 7, 2023.
Who owns ChengDa Pharmaceuticals Co. Ltd.
- Insiders 49.31%
- Institutions 3.16%
- Public & others 47.53%
- Shares outstanding 155M
- Free float 81.1M
ChengDa Pharmaceuticals Co. Ltd. company profile
- Company name
- ChengDa Pharmaceuticals Co. Ltd.
- Ticker
- 301201.SHE
- ISIN
- CNE100005766
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 659
- Fiscal year end
- December
- Address
- No. 36, Huanghe Road, Jiaxing, China, 314100
- Phone
- 86 573 8460 1188
- Website
- chengdapharm.com
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, musculoskeletal system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates. ChengDa Pharmaceuticals Co., Ltd. was founded in 1980 and is based in Jiaxing, China.
ChengDa Pharmaceuticals Co. Ltd. management
8- Mr. Gang LuGM & Director · born 1975
- Mr. Chao FeiChief Financial Officer & Chief Accountant · born 1979
- Mr. Honglin HuangDeputy GM & Director · born 1962
- Ms. Jin LuDeputy GM & Director · born 1978
- Ms. Xiaojing YangDeputy GM & Secretary · born 1982
- Mr. Zhiyong PengDeputy General Manager · born 1980
- Mr. Bao HuDeputy General Manager · born 1983
- Ms. Min Wei ZhaoDeputy General Manager · born 1983